X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly ...

The OMass partnership will boost Roche’s strategy in inflammatory bowel diseases, currently led by afimkibart, an anti-TL1A ...

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program. | Roche’s Genentech unit has handed over ...

Genentech’s initial investment in North Carolina is estimated at more than $700m and is part of Roche’s $50bn commitment to ...

Among the three FDA-approved treatments, SPINRAZA and ZOLGENSMA are leading the market, with SPINRAZA securing a notable ...

Eli Lilly and Novo Nordisk already produce popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site ...

OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their ...

Genentech breaks ground on a new facility in Holly Springs, North Carolina, marking the state's growth in biotech.

Biotechnology pioneer Genentech broke ground Monday on a $700 million manufacturing facility in Holly Springs, marking the ...

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in ...

Genentech, a member of the Roche Group, has commenced construction of a new manufacturing site in Holly Springs, North ...

A biotechnology company set to bring hundreds of new jobs to the Triangle area broke ground on its new manufacturing plant in southern Wake County on Monday.